文献速递骨软组织肉瘤与黑色素瘤

条件生存:局部区域转移性黑色素瘤初诊和治疗后时间点的预后评估

Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis.
PubMed 文献 · J Clin Oncol · 2017-04-04

基于单中心4540例III期黑色素瘤患者,评估初诊时或复发时诊断为III期的条件生存。结果显示,诊断时年龄较大者各条件生存时间点预后更差,男性在条件生存前2年MSS显著更差,IIIB和IIIC期分别生存3年和5年后MSS与IIIA期相似。作者认为辅助全身治疗在诊断后前2年获益最大。

要点

  • III期黑色素瘤诊断时年龄较大者,各条件生存时间点预后更差。
  • 男性在条件生存前2年MSS显著更差,之后与女性相似。
  • IIIB和IIIC期分别生存3年和5年后,MSS与IIIA期相似。

核心结论

  • 作者认为辅助全身治疗在III期黑色素瘤诊断后前2年内给药可能获益最大,此期间年龄较大男性和AJCC亚期较差者预后显著更差。
  • 条件生存估计显示随访患者生存前景改善,可能界定诊断后风险增加的有限时期。

研究设计与样本

  • 单中心队列研究,纳入4540例III期黑色素瘤患者。
  • 初诊时III期患者2042例,原发诊断后首次复发为局部区域转移者2498例。
  • 条件黑色素瘤特异性生存(MSS)估计至诊断后5年,校正年龄、性别和第8版AJCC分期。

主要发现

  • 诊断时年龄较大者各条件生存时间点预后更差。
  • 男性条件生存前2年MSS显著更差,之后男女MSS相似。
  • AJCC IIIB期和IIIC期患者分别生存3年和5年后,MSS与IIIA期患者相似。

关键数值与推荐

  • 初诊时III期患者2042例,复发时III期患者2498例。
  • 条件MSS估计至诊断后5年,校正年龄、性别和第8版AJCC分期。

临床怎么用

  • 条件生存估计可为患者和临床医生提供关键预后信息。
  • 条件生存估计可指导后续癌症随访计划。
  • 条件生存估计可影响治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Standard cancer staging and prognostic estimates are determined at the time of the patient's initial disease presentation. Conditional survival is an alternative, dynamic assessment from follow-up time points after the initial disease diagnosis and is based on the condition of survivorship. Estimates of conditional survival can provide critical prognostic information for patients and clinicians, guide subsequent cancer follow-up schedules, and influence decisions regarding treatments. The current study presents conditional survival estimates developed from a cohort of 4,540 patients diagnosed with stage III melanoma treated at a single institution. Methods Patients with stage III disease at first melanoma diagnosis (initial; n = 2,042), or who developed locoregional metastasis as a first recurrence some time after primary diagnosis (recurrent; n = 2,498), were assessed. Conditional melanoma-specific survival (MSS) estimates up to 5 years after diagnosis were adjusted for age, sex, and 8th edition American Joint Committee on Cancer (AJCC) stage. Results Older age at diagnosis of stage III disease conveyed a worse prognosis at each conditional survival time point. Males had significantly worse MSS outcomes for up to 2 years of conditional survival, after which males and females had similar MSS. For patients with AJCC stage IIIB and stage IIIC disease, MSS outcomes were similar to those of patients with stage IIIA disease after 3 and 5 years of survivorship, respectively. Conclusion Adjuvant systemic treatments may have the greatest benefit when administered within the first 2 years of stage III melanoma diagnosis, during which period prognosis is significantly worse for male patients of increasing age and AJCC substage. Conditional survival estimates illustrate improved survival prospects for patients with cancer returning for follow-up and may define a finite period of increased risk after diagnosis.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Haydu LE, Scolyer RA, Lo S, et al. Conditional Survival: An Assessment of the Prognosis of Patients at Time Points After Initial Diagnosis and Treatment of Locoregional Melanoma Metastasis. J Clin Oncol. 2017. PMID: 28375785. doi:10.1200/JCO.2016.71.9393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。